FDA Explores AI Integration for Drug Evaluation

According to ShibDaily, OpenAI has been in discussions with the U. S. Food and Drug Administration (FDA) about expanding the agency's use of artificial intelligence (AI) to enhance drug evaluation processes. The discussions reportedly focus on a potential AI initiative named 'cderGPT,' aimed at supporting the FDA's Center for Drug Evaluation source: https://www.binance.com/en/square/post/24274436943809?utm_source=BinanceNewsRSS